22717-56-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
METHYL 4-BROMO-2-HYDROXYBENZOATE is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its chemical structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Food Industry:
In the food industry, METHYL 4-BROMO-2-HYDROXYBENZOATE is used as a flavoring agent. Its unique taste profile contributes to the flavor of various food products, enhancing the overall sensory experience for consumers.
Used in Cosmetic and Personal Care Products:
METHYL 4-BROMO-2-HYDROXYBENZOATE is incorporated into cosmetic and personal care products as an ingredient. Its properties may contribute to the efficacy and performance of these products, providing benefits such as improved skin health and appearance.
Used in Laboratory Synthesis:
In the laboratory, METHYL 4-BROMO-2-HYDROXYBENZOATE is used in the synthesis of various organic compounds. Its reactivity and functional groups make it a valuable building block for the development of new chemical entities with potential applications in research and industry.
Safety Precautions:
It is important to handle METHYL 4-BROMO-2-HYDROXYBENZOATE with care, as it can be harmful if ingested, inhaled, or comes into contact with skin and eyes. Proper safety measures, such as wearing protective gear and following handling protocols, should be strictly adhered to during its use in any application.

InChI:InChI=1/C8H7BrO3/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4,10H,1H3

Upstream product

• 67-56-1 methanol 
• 1666-28-0 4-bromosalicylic acid 
• 65-49-6 4-Aminosalicylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 61799-79-9 4-bromo-2-hydroxy-benzenecarbohydroxamic acid 
• 1235837-75-8 methyl 4-bromo-2-(2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetoxy)benzoate 
• 1312610-35-7 C₁₁H₉BrO₃ 
• 5428-40-0 4-bromo-2-hydroxybenzamide 
• 1620885-46-2 7-bromo-1‘-(3,4-difluorobenzyl)-spiro[benzo[e][1,3]oxazine-2,4’-piperidin]-4(3H)-one 
• 1620884-98-1 7-bromo-1’-(3,4-difluorobenzyl)-3-(4-methoxyphenyl)-spiro[benzo[e][1,3]oxazine-2,4’-piperidin]-4(3H)-one 
• 1228095-06-4 C₁₅H₁₃BrO₃ 
• 1221891-23-1 4-bromo-2-(naphthalen-1-ylmethoxy)benzoic acid 

Relevant academic research and scientific papers

De Novo Design of Bioactive Small Molecules by Artificial Intelligence

Generative artificial intelligence offers a fresh view on molecular design. We present the first-time prospective application of a deep learning model for designing new druglike compounds with desired activities. For this purpose, we trained a recurrent neural network to capture the constitution of a large set of known bioactive compounds represented as SMILES strings. By transfer learning, this general model was fine-tuned on recognizing retinoid X and peroxisome proliferator-activated receptor agonists. We synthesized five top-ranking compounds designed by the generative model. Four of the compounds revealed nanomolar to low-micromolar receptor modulatory activity in cell-based assays. Apparently, the computational model intrinsically captured relevant chemical and biological knowledge without the need for explicit rules. The results of this study advocate generative artificial intelligence for prospective de novo molecular design, and demonstrate the potential of these methods for future medicinal chemistry.

Peptidomimetic analogues of an Arg-Trp-x-x-Trp motif responsible for interaction of translocase MraY with bacteriophage ?X174 lysis protein E

Translocase MraY is the target for bacteriophage ?X174 lysis protein E, which interacts via a protein–protein interaction mediated by Phe-288 and Glu-287 of E. coli MraY, and an Arg-Trp-x-x-Trp motif on protein E, also found in several cationic antimicrob

Development of DHQ-based chemical biology probe to profile cellular targets for HBV

Chronic hepatitis B virus (HBV) infection has been a serious public health burden worldwide. Current anti-HBV therapies could not eliminate HBV ultimately. Considering the characteristics of HBV, it is impossible to be entirely cured based on current therapies. Therefore, it is urgently needed to develop novel therapeutic agents with new mechanism of action. The dihydroquinolizinone (DHQ) derivatives exhibited potent anti-HBV activity by decreasing HBV DNA and HBsAg level in an obscure mechanism of action. In this study, we have optimized the DHQ scaffold, developed the photoaffinity probe, with which to identify potential binding proteins.

Synthesis and biological evaluation of novel 5,6,7-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents

5,6,7-Trimethoxy flavonoid salicylate derivatives were designed by the joining of three important pharmacophores (TMP, flavonoid, and SA) according to the combination principle. A series of novel trimethoxy flavonoid salicylate derivatives were synthesized and their in vitro anti-tumor activities were evaluated. Among these derivatives, compound 7f exhibited excellent antiproliferative activity against HGC-27 cells and MGC-803 cells with IC50 values of 10.26 ± 6.94 μM and 17.17 ± 3.03 μM, respectively. Subsequently, the effects on cell colony formation (clonogenic survival assay), cell migration (wound healing assay), cell cycle distribution (PI staining assay), cell apoptosis (Hoechst 33258 staining assay and annexin V-FITC/PI dual staining assay), lactate level (lactate measurement), microtubules disarrangement (immunofluorescence staining analysis) and docking posture (molecular docking simulation) were determined. Further western blot analysis confirmed that compound 7f could effectively down-regulate the expression of glycolysis-related proteins HIF-1α, PFKM and PKM2 and tumor angiogenesis-related proteins VEGF. Overall, these studies suggested that compound 7f, as the representative compound of those, might be a promising candidate for the treatment of gastric cancer and deserved the further studies.

Preparation method of tricyclic compound drug intermediate for regulating activity of FXR

The invention discloses a preparation method of a tricyclic compound drug intermediate for regulating the activity of a Farniol x receptor (FXR). The method comprises the following steps: firstly, esterifying 4-bromosalicylic acid and methanol to obtain 4

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Design, synthesis, and preliminary biological evaluation of 3′,4′,5′-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents

According to the pharmacophore combination principle, a set of new 3′,4′,5′-trimethoxy flavonoid salicylate derivatives were designed, synthesized, and evaluated for biological activity. The cytotoxicity evaluation revealed that compound 10v exhibited higher potency than 5-Fu against HCT-116 cells. Preliminary biological activity studies showed that compound 10v could inhibit the colony formation and migration of HCT-116 cells. Besides, the Hoechst 33258 staining assay and flow cytometry revealed that treatment with compound 10v induced the apoptosis of HCT-116 cells in a concentration-dependent manner, while it had no effect on their cell cycle. The WB analysis suggested that HIF-1α, tubulin, HK-2, and PFK might be the potential pharmacophore targets of compound 10v. Tubulin was a potential drug target for compound 10v, which was explained by analyzing the crystal structure of compound 10v complexed with tubulin. These results indicated that compound 10v might be a promising anti-tumor agent candidate, deserving further optimization and evaluation.

Temperature-Controlled Evolution of Nanoporous MOF Crystallites into Hierarchically Porous Superstructures

Sophisticated multichannel tubular structures have long been utilized in biological systems. However, the well-controlled assembly of biomimetic materials utilizing these features still remains a challenge. Herein, we report an unexpected one-pot fabrication of biomimetic hierarchically porous metal-organic framework (MOF) tubular superstructures. This temperature-controlled structural evolution was investigated under solvothermal conditions: crystalline hollow MOF tubes can be obtained via self-templating and self-healing at higher temperatures, whereas hierarchical helical or multichannel tubular superstructures are fabricated through a helical or oriented evolution process at lower temperatures. Our work here presents the first example of tubular MOF superstructures and highlights the unexpected power of self-assembly and healing during structural evolution process. It has been widely observed in various scales that complex systems have a hierarchical or multilevel organization. For instance, hierarchical tubular structures are commonly adopted in natural systems, including bears and bamboo, as a result of long-term evolution, which can help enhance fluid transportation in plants, reduce the overall weight of animals, and prevent heat transfer. Our discovery here mimics the natural evolution and generates a series of hierarchically porous metal-organic framework (MOF) superstructures through self-templating, self-healing, and oriented evolution. This facile strategy provides fresh insights into MOF growth and oriented evolution mechanisms, enabling the state-of-the-art design of multichannel materials with promising applications in water harvesting and transport, multicomponent drug delivery, efficient catalysis, and fabrication of multichannel carbon rods for energy storage. Hierarchically porous superstructures have been successfully assembled from nanoporous MOF crystallites. Benefiting from the dynamic coordination bond formation, hierarchical helical or multichannel tubular superstructures can be accessed through oriented assembly of MOF crystallites. This temperature-controlled structural evolution also enables the formation of crystalline hollow MOF tubes via self-templating and self-healing processes. Further incorporation of multiple components into these frameworks provides a fresh route for preparing stable, multivariate, and hierarchical frameworks with accessible catalytically active sites for heterogeneous catalysis.

FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The invention also relates to the use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.